90 related articles for article (PubMed ID: 19435451)
1. Bringing protein biomarker discovery to the clinic.
Waybright TJ; Veenstra TD
Expert Rev Mol Diagn; 2009 May; 9(4):305-7. PubMed ID: 19435451
[No Abstract] [Full Text] [Related]
2. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry.
Siu KW; DeSouza LV; Scorilas A; Romaschin AD; Honey RJ; Stewart R; Pace K; Youssef Y; Chow TF; Yousef GM
J Proteome Res; 2009 Aug; 8(8):3797-807. PubMed ID: 19610612
[TBL] [Abstract][Full Text] [Related]
3. Proteomics discovery of biomarkers.
Massé R; Gibbs BF
Methods Biochem Anal; 2005; 45():181-216. PubMed ID: 19235296
[No Abstract] [Full Text] [Related]
4. A new strategy for protein biomarker discovery utilizing 2-nitrobenzenesulfenyl (NBS) reagent and its applications to clinical samples.
Matsuo E; Watanabe M; Kuyama H; Nishimura O
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Sep; 877(25):2607-14. PubMed ID: 19535307
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Clostridium species utilizing liquid chromatography/mass spectrometry of intact proteins.
Everley RA; Mott TM; Toney DM; Croley TR
J Microbiol Methods; 2009 May; 77(2):152-8. PubMed ID: 19318054
[TBL] [Abstract][Full Text] [Related]
6. Renal cell carcinoma with extensive clear cell change sharing characteristics of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma.
Kuroda N; Tamura M; Hes O; Michal M; Kawada C; Shuin T; Lee GH
Pathol Int; 2009 Sep; 59(9):687-8. PubMed ID: 19712140
[No Abstract] [Full Text] [Related]
7. Kidney cancer: Mice with Flcn knockout in proximal tubules-an in vivo model for multiple RCC subtypes.
Thoma C
Nat Rev Urol; 2015 Aug; 12(8):420. PubMed ID: 26150235
[No Abstract] [Full Text] [Related]
8. Translocation carcinoma of the kidney.
Paras FA; MacLennan GT
J Urol; 2008 May; 179(5):2007. PubMed ID: 18355851
[No Abstract] [Full Text] [Related]
9. Expression and mutational analyses of KIT and PDGFR-alpha in sarcomatoid renal cell carcinoma.
Petit A; Castillo M; Gaspa A; Colomer D; Garcia de Albéniz X; Moreno C; Camós M; Mellado B; Mallofré C
Histopathology; 2009 Aug; 55(2):230-2. PubMed ID: 19694830
[No Abstract] [Full Text] [Related]
10. Informed use of proteolytic inhibitors in biomarker discovery.
Bergen HR; Klug MG; Bolander ME; Muddiman DC
Rapid Commun Mass Spectrom; 2004; 18(9):1001-2. PubMed ID: 15116428
[No Abstract] [Full Text] [Related]
11. Specific reduction of fas-associated protein with death domain (FADD) in clear cell renal cell carcinoma.
Xu H; He L; Feng X; Kapoor A; Tang D
Cancer Invest; 2009 Oct; 27(8):836-43. PubMed ID: 19557578
[TBL] [Abstract][Full Text] [Related]
12. Kidney cancer: past, present, and future.
Novick AC
Urol Oncol; 2007; 25(3):188-95. PubMed ID: 17483014
[No Abstract] [Full Text] [Related]
13. Identification of two new serum protein profiles for renal cell carcinoma.
Engwegen JY; Mehra N; Haanen JB; Schellens JH; Voest EE; Beijnen JH
Oncol Rep; 2009 Aug; 22(2):401-8. PubMed ID: 19578783
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Csk-binding protein contributes to renal cell carcinogenesis.
Feng X; Lu X; Man X; Zhou W; Jiang LQ; Knyazev P; Lei L; Huang Q; Ullrich A; Zhang Z; Chen Z
Oncogene; 2009 Sep; 28(37):3320-31. PubMed ID: 19581936
[TBL] [Abstract][Full Text] [Related]
15. Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
Balamurugan K; Luu VD; Kaufmann MR; Hofmann VS; Boysen G; Barth S; Bordoli MR; Stiehl DP; Moch H; Schraml P; Wenger RH; Camenisch G
Oncogene; 2009 Sep; 28(37):3274-85. PubMed ID: 19581925
[TBL] [Abstract][Full Text] [Related]
16. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification.
Zhou M; Yang XJ; Lopez JI; Shah RB; Hes O; Shen SS; Li R; Yang Y; Lin F; Elson P; Sercia L; Magi-Galluzzi C; Tubbs R
Am J Surg Pathol; 2009 Dec; 33(12):1840-9. PubMed ID: 19898225
[TBL] [Abstract][Full Text] [Related]
17. Characterization of HLA-G expression in renal cell carcinoma.
Li BL; Lin A; Zhang XJ; Zhang X; Zhang JG; Wang Q; Zhou WJ; Chen HX; Wang TJ; Yan WH
Tissue Antigens; 2009 Sep; 74(3):213-21. PubMed ID: 19531101
[TBL] [Abstract][Full Text] [Related]
18. Fluorescent cytogenetics of renal cell neoplasms.
Brunelli M; Gobbo S; Cossu-Rocca P; Cheng L; Ficarra V; Novara G; Menestrina F; Chilosi M; Martignoni G
Pathologica; 2008 Dec; 100(6):454-60. PubMed ID: 19475886
[TBL] [Abstract][Full Text] [Related]
19. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival.
Zubac DP; Bostad L; Kihl B; Seidal T; Wentzel-Larsen T; Haukaas SA
J Urol; 2009 Nov; 182(5):2144-9. PubMed ID: 19758660
[TBL] [Abstract][Full Text] [Related]
20. A case of oncocytic papillary renal cell carcinoma.
Okada A; Sasaki S; Fujiyoshi Y; Niimi K; Kurokawa S; Umemoto Y; Kohri K
Int J Urol; 2009 Sep; 16(9):765-7. PubMed ID: 19769658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
